Business Context and Reporting Period
This Form 8-K filing by Alphatec Holdings, Inc. is dated March 3, 2017. The report addresses a corporate governance issue regarding the composition of the Board of Directors following the resignation of director Siri S. Marshall on February 8, 2017.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on regulatory compliance and board composition.
Material Changes
The material change reported is the reduction of the Audit Committee to two independent directors due to Ms. Marshall's resignation. Consequently, the Company received a notice from the Nasdaq Stock Market stating it is no longer in compliance with Nasdaq Listing Rule 5605, which mandates a minimum of three independent directors on the Audit Committee.
Guidance, Outlook, and Risks
Compliance Status: The Company is currently non-compliant with Nasdaq listing standards regarding the Audit Committee.
Cure Period: The Company has been granted a cure period under Nasdaq Listing Rule 5605(c)(4) to regain compliance. The deadline is the earlier of the next annual meeting of stockholders or February 8, 2018. If the next annual meeting is held before August 7, 2017, the deadline is August 7, 2017.
Management Action: Management intends to appoint an additional independent director to the Audit Committee prior to the end of the cure period.
Key Facts for Investor Verification
- Verify the appointment of a new independent director to the Audit Committee before the applicable cure period deadline.
- Monitor future filings for confirmation of restored compliance with Nasdaq Listing Rule 5605.
- Confirm the date of the next annual meeting of stockholders to determine the exact compliance deadline.